Savoie Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$14.7M Sell
18,816
-100
-0.5% -$77.7K 1.82% 12
2025
Q1
$14.6M Hold
18,916
1.74% 14
2024
Q4
$14.6M Buy
18,916
+700
+4% +$580K 1.74% 14
2024
Q3
$16.1M Buy
18,216
+1,300
+8% +$1.17M 1.97% 13
2024
Q2
$15.3M Buy
+16,916
New +$13.5M 1.98% 13
2024
Q1
Sell
-10,000
Closed -$5.83M 92
2023
Q4
$5.83M Buy
10,000
+3,084
+45% +$1.8M 1.33% 23
2023
Q3
$3.71M Buy
+6,916
New +$3.56M 0.97% 27

Other funds holding LLY

Savoie Capital's LLY Position: Q2 2025 in Review

Savoie Capital reduced its Eli Lilly (LLY) stake by 0.53% in Q2 2025, selling an estimated $77.7K and leaving 18,816 shares worth $14.7M. The position accounts for 1.82% of the portfolio, ranked #12.

Savoie Capital first reported a position in LLY in Q3 2023 and has held it in 7 quarters since. The position peaked at $16.1M in Q3 2024. 3,906 funds tracked by Wall St. Rank hold LLY as of Q2 2025.

  • Savoie Capital held 18,816 shares of Eli Lilly worth $14.7M as of Q2 2025.
  • Savoie Capital sold 100 Eli Lilly shares in Q2 2025, an estimated $77.7K.
  • Eli Lilly made up 1.82% of Savoie Capital's portfolio in Q2 2025, its #12 holding.
  • Savoie Capital first reported a position in Eli Lilly in Q3 2023 and has held it in 7 quarters since.
  • Savoie Capital's Eli Lilly position peaked at $16.1M in Q3 2024.
  • 3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2025.

Based on Savoie Capital's 13F filing for Q2 2025, filed 14 Aug 2025.